Pharma
Resources
FAST's mission extends beyond guiding potential therapeutics through the drug development pipeline. We also aspire to share our accumulated knowledge with those who have an interest in participating in AS treatment development. Our aim is to prevent redundant efforts and the waste of valuable time and resources by providing insights and expertise to others in this space.
FAST Bioresources
FAST's has curated bioresources for industry and research partners with the goal of offering resources, insights, and catalog available tools to streamline therapeutic development for the field.
If you are interested in learning more about any of the following resources, please contact us at science@cureangelman.org.
Angelman Syndrome Biomarker and Outcome Measure (A-BOM) Consortium
The A-BOM Consortium is made up of a team of over 350 people that have interest in advancing the regulatory science for Angelman syndrome to understand, develop, test, and validate different tools that can assess meaningful clinical outcomes for individuals living with Angelman syndrome.
For more information about A-BOM, please visit here.
Rush F.A.S.T. Center for Translational Research
In December 2022, FAST announced a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.
Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.
Learn more by clicking here.